Concurrent presence of inflammation and obstructive sleep apnea exacerbates the risk of metabolic syndrome: A KoGES 6-year follow-up study

Jinkwan Kim, Dae Wui Yoon, Seung Ku Lee, Seung Kwan Lee, Kyung Mee Choi, Thomas J. Robert, Chol Shin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Obstructive sleep apnea (OSA) leads to multiple end-organ morbidities that are mediated by the cumulative burden of oxidative stress and inflammation. Both OSA and inflammation play key roles in increased risk of cardiovascular disease (CVD). Thus, we hypothesized that the combination of inflammation and OSA could accelerate the development of metabolic syndrome (MetS) in a large cohort study. A total of 1835 participants were randomly selected from the ongoing Korean Genome and Epidemiology Study for the years between 2007 and 2015. Overnight polysomnography was performed on each participant. Blood was drawn for biochemical analyses. Participants with high or low inflammation were divided by high-sensitivity C-reactive protein (hsCRP). MetS was defined using the criteria of the modified National Cholesterol Education Program, Adult Treatment Panel III. The prevalence ofMetSwas higheramong the subjects withOSAand high hsCRPlevels than among the other corresponding groups. The incidence ofMetSamong the 4 groups stratified byOSA and inflammation status at the 6-year follow-up was 11.8%, 19.9%, 25.8%, and 36.0%(HsCRP[-]/OSA[-] vsHsCRP[+]/OSA[-] vsHsCRP[-]/OSA[+] vs HsCRP[+]/OSA[+], P<0.01). After adjusting for age, sex, smoking, alcohol status,BMI, and change inBMI (DBMI) in amultiple logistic regression, the subjectswithOSA and high hsCRP levels at follow-up had a 2.22-fold risk of developing MetS, as compared with those with no-OSA and low hsCRP levels (P<0.01). MetS is more prevalent in the concurrent presence of inflammation and OSA. The combination of these conditions is associated with higher risk of MetS. Additional research is needed to help further define the significance of the combined effect of OSA and subclinical inflammation on the development of MetS in the context of reduction of CVD risk.

Original languageEnglish
Article numbere4488
JournalMedicine (United States)
Volume96
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Obstructive Sleep Apnea
Inflammation
C-Reactive Protein
Cardiovascular Diseases
Polysomnography
Epidemiology
Oxidative Stress
Cohort Studies
Logistic Models
Smoking
Cholesterol
Alcohols
Genome
Morbidity
Education
Incidence

Keywords

  • Cardiovascular disease
  • High-sensitivity C-reactive protein
  • Inflammation
  • Metabolic syndrome
  • Obstructive sleep apnea

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Concurrent presence of inflammation and obstructive sleep apnea exacerbates the risk of metabolic syndrome : A KoGES 6-year follow-up study. / Kim, Jinkwan; Yoon, Dae Wui; Lee, Seung Ku; Lee, Seung Kwan; Choi, Kyung Mee; Robert, Thomas J.; Shin, Chol.

In: Medicine (United States), Vol. 96, No. 7, e4488, 2017.

Research output: Contribution to journalArticle

@article{adcac18323344daaae6fc84a49ca20af,
title = "Concurrent presence of inflammation and obstructive sleep apnea exacerbates the risk of metabolic syndrome: A KoGES 6-year follow-up study",
abstract = "Obstructive sleep apnea (OSA) leads to multiple end-organ morbidities that are mediated by the cumulative burden of oxidative stress and inflammation. Both OSA and inflammation play key roles in increased risk of cardiovascular disease (CVD). Thus, we hypothesized that the combination of inflammation and OSA could accelerate the development of metabolic syndrome (MetS) in a large cohort study. A total of 1835 participants were randomly selected from the ongoing Korean Genome and Epidemiology Study for the years between 2007 and 2015. Overnight polysomnography was performed on each participant. Blood was drawn for biochemical analyses. Participants with high or low inflammation were divided by high-sensitivity C-reactive protein (hsCRP). MetS was defined using the criteria of the modified National Cholesterol Education Program, Adult Treatment Panel III. The prevalence ofMetSwas higheramong the subjects withOSAand high hsCRPlevels than among the other corresponding groups. The incidence ofMetSamong the 4 groups stratified byOSA and inflammation status at the 6-year follow-up was 11.8{\%}, 19.9{\%}, 25.8{\%}, and 36.0{\%}(HsCRP[-]/OSA[-] vsHsCRP[+]/OSA[-] vsHsCRP[-]/OSA[+] vs HsCRP[+]/OSA[+], P<0.01). After adjusting for age, sex, smoking, alcohol status,BMI, and change inBMI (DBMI) in amultiple logistic regression, the subjectswithOSA and high hsCRP levels at follow-up had a 2.22-fold risk of developing MetS, as compared with those with no-OSA and low hsCRP levels (P<0.01). MetS is more prevalent in the concurrent presence of inflammation and OSA. The combination of these conditions is associated with higher risk of MetS. Additional research is needed to help further define the significance of the combined effect of OSA and subclinical inflammation on the development of MetS in the context of reduction of CVD risk.",
keywords = "Cardiovascular disease, High-sensitivity C-reactive protein, Inflammation, Metabolic syndrome, Obstructive sleep apnea",
author = "Jinkwan Kim and Yoon, {Dae Wui} and Lee, {Seung Ku} and Lee, {Seung Kwan} and Choi, {Kyung Mee} and Robert, {Thomas J.} and Chol Shin",
year = "2017",
doi = "10.1097/MD.0000000000004488",
language = "English",
volume = "96",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Concurrent presence of inflammation and obstructive sleep apnea exacerbates the risk of metabolic syndrome

T2 - A KoGES 6-year follow-up study

AU - Kim, Jinkwan

AU - Yoon, Dae Wui

AU - Lee, Seung Ku

AU - Lee, Seung Kwan

AU - Choi, Kyung Mee

AU - Robert, Thomas J.

AU - Shin, Chol

PY - 2017

Y1 - 2017

N2 - Obstructive sleep apnea (OSA) leads to multiple end-organ morbidities that are mediated by the cumulative burden of oxidative stress and inflammation. Both OSA and inflammation play key roles in increased risk of cardiovascular disease (CVD). Thus, we hypothesized that the combination of inflammation and OSA could accelerate the development of metabolic syndrome (MetS) in a large cohort study. A total of 1835 participants were randomly selected from the ongoing Korean Genome and Epidemiology Study for the years between 2007 and 2015. Overnight polysomnography was performed on each participant. Blood was drawn for biochemical analyses. Participants with high or low inflammation were divided by high-sensitivity C-reactive protein (hsCRP). MetS was defined using the criteria of the modified National Cholesterol Education Program, Adult Treatment Panel III. The prevalence ofMetSwas higheramong the subjects withOSAand high hsCRPlevels than among the other corresponding groups. The incidence ofMetSamong the 4 groups stratified byOSA and inflammation status at the 6-year follow-up was 11.8%, 19.9%, 25.8%, and 36.0%(HsCRP[-]/OSA[-] vsHsCRP[+]/OSA[-] vsHsCRP[-]/OSA[+] vs HsCRP[+]/OSA[+], P<0.01). After adjusting for age, sex, smoking, alcohol status,BMI, and change inBMI (DBMI) in amultiple logistic regression, the subjectswithOSA and high hsCRP levels at follow-up had a 2.22-fold risk of developing MetS, as compared with those with no-OSA and low hsCRP levels (P<0.01). MetS is more prevalent in the concurrent presence of inflammation and OSA. The combination of these conditions is associated with higher risk of MetS. Additional research is needed to help further define the significance of the combined effect of OSA and subclinical inflammation on the development of MetS in the context of reduction of CVD risk.

AB - Obstructive sleep apnea (OSA) leads to multiple end-organ morbidities that are mediated by the cumulative burden of oxidative stress and inflammation. Both OSA and inflammation play key roles in increased risk of cardiovascular disease (CVD). Thus, we hypothesized that the combination of inflammation and OSA could accelerate the development of metabolic syndrome (MetS) in a large cohort study. A total of 1835 participants were randomly selected from the ongoing Korean Genome and Epidemiology Study for the years between 2007 and 2015. Overnight polysomnography was performed on each participant. Blood was drawn for biochemical analyses. Participants with high or low inflammation were divided by high-sensitivity C-reactive protein (hsCRP). MetS was defined using the criteria of the modified National Cholesterol Education Program, Adult Treatment Panel III. The prevalence ofMetSwas higheramong the subjects withOSAand high hsCRPlevels than among the other corresponding groups. The incidence ofMetSamong the 4 groups stratified byOSA and inflammation status at the 6-year follow-up was 11.8%, 19.9%, 25.8%, and 36.0%(HsCRP[-]/OSA[-] vsHsCRP[+]/OSA[-] vsHsCRP[-]/OSA[+] vs HsCRP[+]/OSA[+], P<0.01). After adjusting for age, sex, smoking, alcohol status,BMI, and change inBMI (DBMI) in amultiple logistic regression, the subjectswithOSA and high hsCRP levels at follow-up had a 2.22-fold risk of developing MetS, as compared with those with no-OSA and low hsCRP levels (P<0.01). MetS is more prevalent in the concurrent presence of inflammation and OSA. The combination of these conditions is associated with higher risk of MetS. Additional research is needed to help further define the significance of the combined effect of OSA and subclinical inflammation on the development of MetS in the context of reduction of CVD risk.

KW - Cardiovascular disease

KW - High-sensitivity C-reactive protein

KW - Inflammation

KW - Metabolic syndrome

KW - Obstructive sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=85013668189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013668189&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000004488

DO - 10.1097/MD.0000000000004488

M3 - Article

C2 - 28207497

AN - SCOPUS:85013668189

VL - 96

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 7

M1 - e4488

ER -